Next Article in Journal
Exploring the Anticancer Effects of Brominated Plastoquinone Analogs with Promising Cytotoxic Activity in MCF-7 Breast Cancer Cells via Cell Cycle Arrest and Oxidative Stress Induction
Next Article in Special Issue
Copper (I)-Chloroquine Complexes: Interactions with DNA and Ferriprotoporphyrin, Inhibition of β-Hematin Formation and Relation to Antimalarial Activity
Previous Article in Journal
Pharmacogenetics of Metformin Transporters Suggests No Association with Therapeutic Inefficacy among Diabetes Type 2 Mexican Patients
 
 
Article

Therapeutic Efficacy of Arnica in Hamsters with Cutaneous Leishmaniasis Caused by Leishmania braziliensis and L. tropica

1
PECET-School of Medicine, University of Antioquia, Calle 70 # 52-21, Medellin 0500100, Colombia
2
University of Münster, Institute of Pharmaceutical Biology and Phytochemistry, PharmaCampus, Corrensstrasse 48, D-48149 Münster, Germany
*
Authors to whom correspondence should be addressed.
Cordially dedicated to Prof. Dr. Andreas Hensel, Münster, Germany, on the occasion of his 60th birthday.
Academic Editors: Gabriela Hrckova and Gustavo Henrique Goulart Trossini
Pharmaceuticals 2022, 15(7), 776; https://doi.org/10.3390/ph15070776
Received: 16 May 2022 / Revised: 9 June 2022 / Accepted: 16 June 2022 / Published: 22 June 2022
Leishmaniasis may occur in three different clinical forms, namely, visceral, mucocutaneous and cutaneous, which are caused by different species of trypanosomatid protozoans of the genus Leishmania. Pentavalent antimonials are the leading treatment for cutaneous leishmaniasis despite the hepatic, renal, and cardiac toxicity. In addition, the response of some Leishmania species to pentavalent antimonials is increasingly poorer, and therefore new and more potent therapeutic alternatives are needed. Arnica montana L., Asteraceae, is a traditional medicinal plant of Europe and preparations of its flowers are commonly used externally to treat disorders of the musculoskeletal system as well as superficial inflammatory conditions. Previous studies have shown that Arnica tincture (AT), an ethanolic extract prepared from the flowerheads of Arnica montana as well as isolated Arnica sesquiterpene lactones (STLs) have antileishmanial activity in vitro against L. donovani and L. infantum, as well as in vivo against L. braziliensis. In this work, we studied the in vitro cytotoxicity and antileishmanial activity of AT and STLs against both L. braziliensis and L. tropica. The in vivo therapeutic effect of AT was studied in hamsters with cutaneous Leishmaniasis (CL) caused by experimental infection with L. braziliensis and L. tropica. Furthermore, various semisolid Arnica preparations were also evaluated against L. braziliensis. The STLs and the AT possess a very high in vitro activity against both Leishmania species with median effective concentrations (EC50) ranging from 1.9 to 5.9 μg/mL. The AT was not cytotoxic for human tissue macrophages, skin fibroblasts, and hepatic cells. The therapeutic response of hamsters infected with L. braziliensis to the topical treatment with AT was 87.5% at a dose of 19.2 μg STL/2× day/60 d, 72.7% at doses of 19.2 μg STL/1× d/60 d and 67% at a dose of 38.4 μg STL/2× d/60 d. In turn, the therapeutic response in hamsters infected with L. tropica was 100% when treated at a dose of 19.2 μg STL/2× day/60 d and 71% at a dose of 38.4 μg STL/2× d/60 d. On the other hand, the effectiveness of treatment with glucantime administered intralesionally at a dose of 200 mg/every three days for 30 days was 62.5% for L. braziliensis and 37.5% for L. tropica infection. These results are promising and encourage the implementation of clinical trials with AT in CL patients as a first step to using AT as a drug against CL. View Full-Text
Keywords: Arnica montana L.; Arnica tincture; natural products; sesquiterpene lactones; cutaneous leishmaniasis; antileishmanial drugs; Leishmania braziliensis; Leishmania tropica; Mesocricetus auratus Arnica montana L.; Arnica tincture; natural products; sesquiterpene lactones; cutaneous leishmaniasis; antileishmanial drugs; Leishmania braziliensis; Leishmania tropica; Mesocricetus auratus
Show Figures

Figure 1

MDPI and ACS Style

Robledo, S.M.; Murillo, J.; Arbeláez, N.; Montoya, A.; Ospina, V.; Jürgens, F.M.; Vélez, I.D.; Schmidt, T.J. Therapeutic Efficacy of Arnica in Hamsters with Cutaneous Leishmaniasis Caused by Leishmania braziliensis and L. tropica. Pharmaceuticals 2022, 15, 776. https://doi.org/10.3390/ph15070776

AMA Style

Robledo SM, Murillo J, Arbeláez N, Montoya A, Ospina V, Jürgens FM, Vélez ID, Schmidt TJ. Therapeutic Efficacy of Arnica in Hamsters with Cutaneous Leishmaniasis Caused by Leishmania braziliensis and L. tropica. Pharmaceuticals. 2022; 15(7):776. https://doi.org/10.3390/ph15070776

Chicago/Turabian Style

Robledo, Sara M., Javier Murillo, Natalia Arbeláez, Andrés Montoya, Victoria Ospina, Franziska M. Jürgens, Iván D. Vélez, and Thomas J. Schmidt. 2022. "Therapeutic Efficacy of Arnica in Hamsters with Cutaneous Leishmaniasis Caused by Leishmania braziliensis and L. tropica" Pharmaceuticals 15, no. 7: 776. https://doi.org/10.3390/ph15070776

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop